Picture of Essex Bio-Technology logo

1061 — Essex Bio-Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Development & Exclusive License Agreement

Oct 15 (Reuters) - Shanghai Henlius Biotech Inc  2696.HK :
    * ENTERED CO-DEVELOPMENT & EXCLUSIVE LICENSE AGREEMENT WITH
ESSEX
BIO-INVESTMENT & ZHUHAI ESSEX BIO-PHARMACEUTICAL
    * TO CO-DEVELOP HLX04 AS THERAPY FOR EYE DISEASES WITH ESSEX
    * CO ENTITLED TO GET SIGNING PAYMENT OF US$10 MILLION AND
REGULATORY MILESTONE PAYMENTS OF NOT MORE THAN US$15 MILLION

Source text for Eikon:  ID:nHKS1pTWvn 
Further company coverage:  2696.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Essex Bio-Technology

See all news